



US009273191B2

(12) **United States Patent**
Ladet et al.

(10) **Patent No.:** **US 9,273,191 B2**
(45) **Date of Patent:** **Mar. 1, 2016**

(54) **MEDICAL DEVICES WITH AN ACTIVATED COATING**

(75) Inventors: **Sébastien Ladet**, Lyons (FR); **Ahmad Robert Hadba**, Middlefield, CT (US)

(73) Assignees: **Sofradim Production** (FR); **Covidien LP**, Mansfield, MA (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 513 days.

(21) Appl. No.: **13/202,390**

(22) PCT Filed: **Feb. 22, 2010**

(86) PCT No.: **PCT/IB2010/000665**

§ 371 (c)(1),

(2), (4) Date: **Oct. 13, 2011**

(87) PCT Pub. No.: **WO2010/095056**

PCT Pub. Date: **Aug. 26, 2010**

(65) **Prior Publication Data**

US 2012/0021037 A1 Jan. 26, 2012

Related U.S. Application Data

(60) Provisional application No. 61/154,383, filed on Feb. 21, 2009.

(51) **Int. Cl.**

A61F 13/00 (2006.01)

C08J 7/04 (2006.01)

A61L 17/14 (2006.01)

A61L 29/08 (2006.01)

A61L 31/10 (2006.01)

(52) **U.S. Cl.**

CPC **C08J 7/047** (2013.01); **A61L 17/145** (2013.01); **A61L 29/085** (2013.01); **A61L 31/10** (2013.01)

(58) **Field of Classification Search**

CPC ... C08L 101/02; A61L 17/145; A61L 29/085; A61L 31/10

See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

3,767,085 A 10/1973 Cannon et al.
4,326,532 A 4/1982 Hammar
4,359,049 A 11/1982 Redl et al.
4,464,321 A 8/1984 Pittalis et al.
4,538,920 A 9/1985 Drake
4,753,536 A 6/1988 Spehar et al.
4,839,345 A 6/1989 Doi et al.
4,857,403 A 8/1989 De Lucca et al.
4,880,662 A 11/1989 Habrich et al.
5,021,207 A 6/1991 De Lucca et al.
5,372,585 A 12/1994 Tiefenbrun et al.
5,455,308 A 10/1995 Bastiaansen
5,562,946 A 10/1996 Fofonoff et al.
5,578,662 A 11/1996 Bennett et al.
5,582,955 A 12/1996 Keana et al.

5,612,050 A 3/1997 Rowe et al.
5,804,318 A 9/1998 Pinchuk et al.
5,911,942 A 6/1999 Fofonoff et al.
6,099,563 A * 8/2000 Zhong 623/1.46
6,107,365 A 8/2000 Bertozzi et al.
6,107,453 A 8/2000 Zuccato et al.
6,312,725 B1 11/2001 Wallace et al.
6,342,591 B1 1/2002 Zamora et al.
6,451,032 B1 9/2002 Ory et al.
6,534,611 B1 3/2003 Darling et al.
6,552,103 B1 4/2003 Bertozzi et al.
6,570,040 B2 5/2003 Saxon et al.
6,576,000 B2 6/2003 Carrison
6,624,245 B2 9/2003 Wallace et al.
6,881,766 B2 4/2005 Hain
6,958,212 B1 10/2005 Hubbell et al.
7,012,126 B2 3/2006 Matsuda et al.
7,105,629 B2 9/2006 Matsuda et al.
7,122,703 B2 10/2006 Saxon et al.
7,144,976 B2 12/2006 Matsuda et al.
7,172,877 B2 2/2007 Ting
7,247,692 B2 7/2007 Laredo
7,294,357 B2 11/2007 Roby
7,371,719 B2 5/2008 Stupp et al.
7,375,234 B2 5/2008 Sharpless et al.
7,560,588 B2 7/2009 Breitenkamp et al.
7,618,944 B2 11/2009 Breitenkamp et al.
7,638,558 B2 12/2009 Breitenkamp et al.
7,667,012 B2 2/2010 Saxon et al.
7,795,355 B2 9/2010 Matyjaszewski et al.
7,807,619 B2 10/2010 Bertozzi et al.
7,981,444 B2 7/2011 Tomalia et al.
7,985,424 B2 7/2011 Tomalia et al.

(Continued)

FOREIGN PATENT DOCUMENTS

BE 1008260 A6 2/1996
EP 0490854 B1 9/1996

(Continued)

OTHER PUBLICATIONS

Q. Shi, et al., "The Immobilization of Proteins on Biodegradable Polymer Fibers via Click Chemistry", *Biomaterials*, 29, (2008), pp. 1118-1126.

Jérôme, et al., "Recent Advances in the Synthesis of Aliphatic Polyesters Ring-Opening Polymerization", *Advanced Drug Delivery Reviews*, 60, (2008), pp. 1056-1076.

Zhang, et al., "2-Azido-2-deoxycellulose: Synthesis and 1,3-Dipolar Cycloaddition", *Helvetica Chimica Acta*, vol. 91, pp. 608-611 (2008).

R. Riva, et al., "Contribution of "Click Chemistry" to the Synthesis of Antimicrobial Aliphatic Copolyester", *Polymer* 49, (2008), pp. 2023-2028.

Baskin, et al., "Copper Free Click Chemistry for Dynamic In Vivo Imaging", *PNAS*, vol. 104, No. 43, (Oct. 23, 2007), pp. 16793-16797.
Codelli, et al., "Second Generation Difluorinated Cyclooctynes for Copper-Free Click Chemistry", *J. Am. Chem. Soc.*, vol. 130, No. 34, (2008), pp. 11486-11493.

Sletten and Bertozzi, "A Hydrophilic Azacyclooctyne for Cu-free Click Chemistry", *Org. Lett.* (2008) 10(14), pp. 3097-3099.

(Continued)

Primary Examiner — Suzanne Ziska

(57) **ABSTRACT**

Implantable medical devices include a substrate having applied thereto a coating including a polymeric material possessing a core and at least one functional group known to have click reactivity.

10 Claims, No Drawings

(56)

References Cited

U.S. PATENT DOCUMENTS

8,034,396	B2	10/2011	Kapiamba et al.	2008/0241892	A1	10/2008	Roitman et al.
2002/0016003	A1	2/2002	Saxon et al.	2008/0242171	A1	10/2008	Huang et al.
2002/0161170	A1	10/2002	Matsuda et al.	2008/0248126	A1	10/2008	Cheng et al.
2002/0169275	A1	11/2002	Matsuda et al.	2008/0267878	A1	10/2008	Robillard et al.
2002/0173616	A1	11/2002	Matsuda et al.	2008/0283572	A1	11/2008	Boyden et al.
2003/0100086	A1	5/2003	Yao et al.	2008/0311412	A1	12/2008	Fokin et al.
2003/0135238	A1	7/2003	Milbocker	2008/0317861	A1	12/2008	Guan
2003/0162903	A1	8/2003	Day	2009/0012457	A1	1/2009	Childers et al.
2003/0199084	A1	10/2003	Saxon et al.	2009/0018646	A1 *	1/2009	Zhao 623/1.43
2003/0205454	A1	11/2003	Hlavinka et al.	2009/0027603	A1	1/2009	Samulski et al.
2004/0170752	A1	9/2004	Luthra et al.	2009/0038701	A1	2/2009	Delmotte
2004/0185053	A1	9/2004	Govindan	2009/0053139	A1	2/2009	Shi et al.
2004/0209317	A1	10/2004	Ting	2009/0054619	A1	2/2009	Baker et al.
2004/0249438	A1 *	12/2004	Lefranc et al. 623/1.15	2009/0061010	A1	3/2009	Zale et al.
2005/0032081	A1	2/2005	Ju et al.	2009/0069561	A1	3/2009	Fokin et al.
2005/0038472	A1	2/2005	Furst	2009/0082224	A1	3/2009	Haddleton et al.
2005/0148032	A1	7/2005	Saxon et al.	2009/0098175	A1 *	4/2009	Buehrer et al. 424/422
2005/0222427	A1	10/2005	Sharpless et al.	2009/0099108	A1	4/2009	Jones
2005/0233389	A1	10/2005	Ting et al.	2009/0124534	A1	5/2009	Reineke et al.
2005/0244453	A1	11/2005	Stucke et al.	2009/0137424	A1	5/2009	Tsao et al.
2006/0018948	A1	1/2006	Guire et al.	2009/0181402	A1	7/2009	Finn et al.
2006/0036022	A1	2/2006	Callaghan et al.	2009/0182151	A1	7/2009	Wu et al.
2006/0085033	A1	4/2006	Criscuolo et al.	2009/0202433	A1	8/2009	Chang et al.
2006/0108393	A1	5/2006	Heinrich et al.	2009/0203131	A1	8/2009	Reineke et al.
2006/0110782	A1	5/2006	Bertozzi et al.	2009/0214755	A1	8/2009	Armani et al.
2006/0142404	A1	6/2006	Berge et al.	2009/0220607	A1	9/2009	Kiser et al.
2006/0147963	A1	7/2006	Barone et al.	2009/0240030	A1	9/2009	Ju et al.
2006/0193865	A1	8/2006	Govindan	2009/0247651	A1	10/2009	Kapiamba et al.
2006/0228300	A1	10/2006	Chang et al.	2009/0250588	A1	10/2009	Robeson et al.
2006/0228357	A1	10/2006	Chang et al.	2009/0253609	A1	10/2009	Fleury et al.
2006/0240092	A1	10/2006	Breitenkamp et al.	2009/0259016	A1	10/2009	Johnson et al.
2006/0276658	A1	12/2006	Saxon et al.	2009/0263468	A1	10/2009	McAnulty et al.
2007/0020620	A1	1/2007	Finn et al.	2009/0269277	A1	10/2009	Chang et al.
2007/0037964	A1	2/2007	Saxon et al.	2009/0281250	A1	11/2009	DeSimone et al.
2007/0060658	A1	3/2007	Diaz et al.	2009/0297609	A1	12/2009	Shoichet et al.
2007/0077564	A1	4/2007	Roitman et al.	2009/0306310	A1	12/2009	Wu et al.
2007/0086942	A1	4/2007	Chang et al.	2009/0312363	A1	12/2009	Bradner et al.
2007/0087001	A1	4/2007	Taylor et al.	2009/0325292	A1	12/2009	Baker et al.
2007/0099251	A1	5/2007	Zhang et al.	2010/0011472	A1	1/2010	Hugel et al.
2007/0140966	A1	6/2007	Chang et al.	2010/0015046	A1	1/2010	Govindan et al.
2007/0178133	A1	8/2007	Rolland	2010/0021391	A1	1/2010	Douglas et al.
2007/0178448	A1	8/2007	Tsao et al.	2010/0034862	A1	2/2010	Laronde et al.
2007/0190597	A1	8/2007	Agnew et al.	2010/0047258	A1	2/2010	Wang et al.
2007/0212267	A1	9/2007	Organ et al.	2010/0048738	A1	2/2010	Fleury et al.
2007/0244265	A1	10/2007	Matyjaszewski et al.	2010/0069578	A1	3/2010	Faust et al.
2007/0244296	A1	10/2007	Tomalia et al.	2010/0098640	A1	4/2010	Cohen et al.
2007/0249014	A1	10/2007	Agnew et al.	2010/0104589	A1	4/2010	Govindan et al.
2007/0254006	A1	11/2007	Loose et al.	2010/0121022	A1	5/2010	Musa et al.
2007/0258889	A1	11/2007	Douglas et al.	2010/0159508	A1	6/2010	Yang et al.
2007/0269369	A1	11/2007	Gegg et al.	2010/0247433	A1	9/2010	Tirrell et al.
2007/0272122	A1	11/2007	Lahann et al.	2010/0286405	A1	11/2010	Fokin et al.
2007/0275387	A1	11/2007	Ju	2010/0291171	A1	11/2010	Crescenzi et al.
2007/0298006	A1	12/2007	Tomalia et al.	2010/0303754	A1	12/2010	Turpin et al.
2008/0015138	A1	1/2008	Hamilton et al.	2011/0008251	A1	1/2011	Chang et al.
2008/0021486	A1	1/2008	Oyola et al.	2011/0052696	A1	3/2011	Hult et al.
2008/0035243	A1	2/2008	Breitenkamp et al.	2011/0060107	A1	3/2011	Matyjaszewski et al.
2008/0038472	A1	2/2008	Suzuki et al.	2011/0143435	A1	6/2011	Stayton et al.
2008/0045686	A1	2/2008	Meagher et al.	2011/0177156	A1	7/2011	Szoka, Jr. et al.
2008/0050731	A1	2/2008	Agnew et al.	2011/0183417	A1	7/2011	Reineke
2008/0051562	A1	2/2008	Chaikof et al.	2011/0213123	A1	9/2011	Bertozzi et al.
2008/0103564	A1	5/2008	Burkinshaw et al.	2011/0257343	A1 *	10/2011	Harth et al. 525/415
2008/0121657	A1	5/2008	Voegelé et al.				
2008/0138317	A1	6/2008	Fung				
2008/0160017	A1	7/2008	Baker et al.				
2008/0166363	A1	7/2008	Govindan et al.				
2008/0171067	A1	7/2008	Govindan et al.				
2008/0187956	A1	8/2008	Carrico et al.				
2008/0199736	A1	8/2008	Gadeken et al.				
2008/0200628	A1	8/2008	Gadeken et al.				
2008/0207913	A1	8/2008	Breitenkamp et al.				
2008/0214436	A1	9/2008	Yu et al.				
2008/0214801	A1	9/2008	Saxon et al.				
2008/0214831	A1	9/2008	Sharpless et al.				
2008/0221043	A1	9/2008	Harth et al.				
2008/0241856	A1	10/2008	Wong et al.				

FOREIGN PATENT DOCUMENTS

EP	1790702	A1	5/2007
EP	1795563	A1	6/2007
EP	1975230	A1	1/2008
EP	2014308	A2	1/2009
EP	2090592	A1	8/2009
WO	WO 2006/012569	A1	2/2006
WO	WO 2007/041394	A2	4/2007
WO	WO 2007/121055	A1	10/2007
WO	WO 2008/013618	A1	1/2008
WO	2008017029	A2	2/2008
WO	WO 2008/075955	A2	6/2008
WO	WO 2008/077406	A2	7/2008
WO	WO 2008/108736	A1	9/2008

(56)

References Cited

FOREIGN PATENT DOCUMENTS

WO WO 2008/115694 A2 9/2008
 WO WO 2008/120016 A1 10/2008
 WO WO 2010/095049 A1 8/2010

OTHER PUBLICATIONS

Cazalis, et al., "C-Terminal Site-Specific PEGylation of a Truncated Thrombomodulin Mutant with Retention of Full Bioactivity", *Bioconjugate Chem.*, (2004), 15, pp. 1005-1009.
 Haridas, et al., "Design and Synthesis of Triazole-based Peptidodendrimers" *Tetrahedron Letters*, vol. 48, (2007), pp. 4719-4722.
 Raghavan, et al., "Chemical Probes for Profiling Fatty Acid-associated Proteins in Living Cells", *Bioorg. Med. Chem. Lett.*, 18 (2008), pp. 5982-5986.
 LeDévédec, et al., "Separation of Chitosan Oligomers by Immobilized Metal Affinity Chromatography", *Journal of Chromatography A.*, 2008, 1194(2), pp. 165-171.
 Hartgerink, et al., "Peptide-amphiphile Nanofibers: A Versatile Scaffold for the Preparation of Self Assembling Materials", *PNAS*, 2002; 99(2), pp. 5133-5138.
 Van Berkel, et al., "Metal-Free Triazole Formation as a Tool for Bioconjugation" *Chem Bio Chem*, 8, (2007), pp. 1504-1508.
 Nottelet, et al., Synthesis of an X-ray opaque biodegradable copolyester by chemical modification of poly (ϵ -caprolactone) *Biomaterials*, 27, (2006), pp. 4943-4954.
 Smith, et al., "Synthesis and Convenient Functionalization of Azide-labeled Diacylglycerol Analogues for Modular Access to Biologically Active Lipid Probes", *Bioconjugate Chem*, 19(9), (2008). pp. 1855-1863.
 Skierka, et al., "The Influence of Different Acids and Pepsin on the Extractability of Collagen From the Skin of Baltic Cod (*Gadus morhua*)", *Food Chemistry*, 105, (2007), pp. 1302-1306.
 Eastoe, "The Amino Acid Composition of Mammalian Collagen and Gelatin", vol. 61, (1955), pp. 589-600.
 Sicherl, et al., "Orthogonally Protected Sugar Diamino Acids as Building Blocks for Linear and Branched Oligosaccharide Mimetics", *Angew. Chem. Int. Ed.* 44, (2005), pp. 2096-2099.
 Laughlin, et al., "In Vivo Imaging of Membrane-Associated Glycans in Developing Zebrafish", *Science*, 320, (2008), pp. 664-667.
 Worch and Wittmann, "Unexpected Formation of Complex Bridged Tetrazoles via Intramolecular 1,3-dipolar Cycloaddition of 1,2-O-cyanoalkylidene Derivatives of 3-azido-3-deoxy-D-allose", *Carbohydrate Research*, 343, (2008), pp. 2118-2129.
 Witczak et al., "A Click Chemistry Approach to Glycomimetics: Michael addition of 2,3,4,6-tetra-O-acetyl-1-thio- β -D-glucopyranose to 4-deoxy-1,2-O-isopropylidene-L-glycero-pent-4-enopyranos-3-ulose-a convenient route to novel 4-deoxy-(1 \rightarrow 5)-5-C-thiodisaccharides", *Carbohydrate Research*, 342, (2007), 1929-1933.
 Marra, et al., "Validation of the Copper(I)-Catalyzed Azide-Alkyne Coupling in Ionic Liquids, Synthesis of a Triazole-Linked C-Disaccharide as a Case Study", *J. Org. Chem* (2008), 73(6), pp. 2458-2461.
 Srinivasachari, et al., "Versatile Supramolecular pDNA Vehicles via "Click Polymerization" of β -cyclodextrin with oligoethyleneamines", *Biomaterials*, 30, (2009), pp. 928-938.

Arora, et al., "A Novel domino-click approach for the synthesis of sugar based unsymmetrical bis-1,2,3-triazoles", *Carbohydrate Research*, 343, (2008), 139-144.
 Chen, et al., "Synthesis of a C₃-symmetric (1 \rightarrow 6)-N-acetyl- β -D-glucosamine Octadecasaccharide using Click Chemistry", *Carbohydrate Research*, 340, (2005), pp. 2476-2482.
 Gouin, et al., "Multi-Mannosides Based on a Carbohydrate Scaffold: Synthesis, Force Field Development, Molecular Dynamics Studies, and Binding Affinities for Lectin Con A", *J. Org. Chem.*, 2007, 72(24), pp. 9032-9045.
 Srinivasachari, Etal., "Effects of Trehalose Click Polymer Length on pDNA Complex Stability and Delivery Efficacy", *Biomaterials*, 28, (2007), pp. 2885-2898.
 Godeau, et al., Lipid-Conjugated Oligonucleotides via "Click Chemistry" Efficiently Inhibit Hepatitis C Virus Translation, *J. med. Chem.*, 2008, 51(15), pp. 2374-4376.
 Zou et al., "Cu-free Cycloaddition for Identifying Catalytic Active Adenylation Domains of Nonribosomal Peptide Synthesis by phage display", *Bioorganic & Medicinal Chemistry Letters*, 18 (2008), pp. 5664-5667.
 Cantel, et al., "Synthesis and Conformational Analysis of a Cyclic Peptide Obtained via *i* to *i* + 4 Intramolecular Side-chain to Side-chain Azide-Alkyne 1,3-Dipolar Cycloaddition" *J. Org. Chem.*, 2008, 73 (15), pp. 5663-5614.
 Dijk, et al., "Synthesis of Peptide-Based Polymers by Microwave-Assisted Cycloaddition Backbone Polymerization", *Biomacromolecules*, 2007, 8(2), pp. 327-330.
 Köster, et al., "Spectroscopic and Electrochemical Studies of Ferrocenyl Triazole Amino Acid and Peptide Bioconjugates Synthesized by Click Chemistry", *Organometallics*, 2008, 27(23) pp. 6326-6332.
 Dijk, et al., "Synthesis and Characterization of Biodegradable Peptide-Based Polymers Prepared by Microwave-Assisted Click Chemistry", *Biomacromolecules*, 2008, 9(10), pp. 2834-2843.
 Jiang, et al., "Amphiphilic PEG/alkyl-grafted comb polylactides", *J. Polymer Science Part B: Polymer Physics*, 45(22), 2007, pp. 5227-5236.
 Ochs, et al., "Low-Fouling, Biofunctionalized, and Biodegradable Click Capsules", *Biomacromolecules*, 2008, 9(12), pp. 3389-3396.
 Beatty and Tirrell, "Two-color Labeling of Temporally Defined Protein Populations in Mammalian Cells", *Bioorg. Med. Chem. Lett.*, 18 (2008), pp. 5995-5999.
 Kolb, et al., "Click Chemistry: Diverse Chemical Function from a Few Good Reactions", *Angewandte Chemie, International Edition*, Jun. 2001, pp. 2004-2021.
 Krouit, et al., "Cellulose surface grafting with polycaprolactone by heterogeneous click-chemistry", *European Polymer Journal* 44, Dec. 2008, pp. 4074-4081.
 Nandivada, et al. "Reactive polymer coatings that 'Click'." *Angewandte Chemie, International Edition* 45, Apr. 2006, pp. 3360-3363.
 Ossipov and Hilborn, Poly(vinyl alcohol)-Based Hydrogels Formed by "Click Chemistry", *Macromolecules* 2006, 39, pp. 1709-1718.
 Binder and Sachsenhofer, "Click Chemistry in Polymer and Materials Science", *Macromolecular Rapid Commun.* 2007, 28, pp. 15-54.
 Australian Examination Report, Application No. 2010215203 dated May 23, 2014.

* cited by examiner

MEDICAL DEVICES WITH AN ACTIVATED COATING

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a U.S. National Stage Application filed under 35 U.S.C. §371(a) of International Application No. PCT/IB2010/000665 filed Feb. 22, 2010, which claims the benefit of and priority to U.S. Provisional Application Ser. No. 61/154,383 filed Feb. 21, 2009, the entire contents of which are incorporated by reference herein.

BACKGROUND

1. Technical Field

The present disclosure relates to implantable devices having coating that imparts an activated surface to the device.

2. Background of Related Art

Methods for making monofilaments that are suitable to fabricate surgical articles, such as sutures, generally include the steps of extruding at least one bioabsorbable or nonbioabsorbable polymer to provide filaments, drawing or stretching the solidified filaments to achieve molecular orientation, and annealing the drawn filaments to relieve internal stresses.

Various spinning methods may be employed, such as melt spinning, gel spinning, wet or dry spinning, and reaction spinning. Melt spinning uses heat and potentially shear to melt the fiber-forming polymer to a viscosity suitable for extrusion through the die or spinneret. After exiting the die, the fiber solidifies by cooling in air or a suitable chilled fluid bath. In solvent spinning, the fiber-forming polymer is dissolved in a suitable organic solvents or solvent mixture to result in a fluid with suitable viscosity for extrusion through a spinneret. The difference between wet and dry spinning is the means by which the fiber solidifies. In dry spinning, the fiber solidifies as the solvent evaporates under a stream of air or inert gas. In wet spinning, the fiber forms by precipitating from solution as a result of dilution in a non-solvent bath or chemical reaction with a crosslinker in the solvent bath. Gel spinning refers to a process similar to solvent spinning except that the polymer is not fully dissolved in the solvent—a high polymer content is used in the process. The chains of the partially solvated polymer are aligned by the shear during the extrusion process. The filaments are further drawn as they are passed through a gas drying then a wet precipitating bath. The resulting fibers have an unusually high degree of alignment and high tensile strength relative to conventional melt or solvent spinning techniques. Reaction spinning involves the formation of filaments from reactive polymers or prepolymers and monomers that are further polymerized and crosslinked during the extrusion process or after the fiber or filament is formed.

Click chemistry refers to a collection of reactions capable of forming a highly reliable molecular connection in solution or bulk state. Click chemistry reactions may be highly selective, high yield reactions which should not interfere with one another as well as other reactions.

It would be desirable to make filaments useful in making surgical devices by extruding a mixture containing first and second precursors functionalized for crosslinking by click chemistry and aided by the process controls of the spinning process, such as temperature, pressure, and time.

SUMMARY

A first aspect of the invention is a method of producing a medical device comprising:

coating a substrate with a polymer possessing a core and at least one functional group known to have click reactivity, whereby a medical device with an activated surface is produced.

In the present application, unless otherwise specified, the expressions “functional group”, “functional group known to have click reactivity” and “reactive member” are used interchangeably to designate a functional group known to have click reactivity.

In the present application, unless otherwise specified, the expression “functionalized polymer” means the polymer possessing the functional group as defined herein.


Another aspect of the invention is a medical device comprising a substrate having a coating, the coating comprising a polymer possessing a functional group having click reactivity.

In embodiments, the substrate is a biocompatible polymeric substrate. The biocompatible polymeric substrate may include fibers, monofilaments, multifilaments, surgical meshes, ligatures, sutures, staples, patches, slings, foams, pellicles, films, barriers, stents, catheters, shunts, grafts, coil, inflatable balloon and combinations thereof.

The core may be prepared from synthetic materials selected from poly(lactic acid), poly(glycolic acid), poly(lactide), poly(glycolide), poly(trimethylene carbonate), poly(p-dioxanone), poly(hydroxybutyrate), poly(phosphazene), polyesters, poly(ethylene terephthalate), ultra-high molecular weight polyethylene, poly(ethylene glycol)s, poly(ethylene oxide)s, poly(acrylamides), poly(hydroxyethyl methacrylate), poly(vinylpyrrolidone), poly(vinyl alcohol)s, poly(acrylic acid), polyacetate, polycaprolactone, polypropylene, aliphatic polyesters, glycerols, poly(amino acids), copoly(ether-esters), poly(alkylene oxalate)s, poly(saccharides), polyamides, poly(iminocarbonates), polyoxaesters, polyorthoesters, polyphosphazenes, biopolymers, polymer drugs and copolymers, block copolymers, homopolymers, blends and combinations thereof.

In embodiments, the core may be prepared from natural polymers selected from collagen, cellulose, poly(amino acids), polysaccharides, chitosan and chitosan derivatives (e.g., chitosan acetate/formate polymers), hyaluronic acid, gut, copolymers and combinations thereof.

In embodiments, the functional group known to have click reactivity is selected from the group consisting in an amine, sulfate, thiols, hydroxyl, azides, alkynes, alkenes, carboxyl groups, aldehyde groups, sulfone groups, vinylsulfone groups, isocyanate groups, acid anhydride groups, epoxide groups, aziridine groups, episulfide groups, groups such as $-\text{CO}_2\text{N}(\text{COCH}_2)_2$, $-\text{CO}_2\text{N}(\text{COCH}_2)_2$, $-\text{CO}_2\text{H}$, $-\text{CHO}$, $-\text{CHOCH}_2$, $-\text{N}=\text{C}=\text{O}$, $-\text{SO}_2\text{CH}=\text{CH}_2$, $-\text{N}(\text{COCH}_2)_2$, $-\text{S}-\text{S}-(\text{C}_5\text{H}_4\text{N})$, and/or groups of the following structures wherein X is halogen and R is hydrogen or C_1 to C_4 alkyl:



For example, the functional group known to have click reactivity is selected from the group consisting in thiols, azides, alkynes and alkenes.

In particular, the functional group known to have click reactivity may be a thiol. Alternatively, the functional group known to have click reactivity may be an azide. Alternatively, the functional group known to have click reactivity may be an alkyne. Alternatively, the functional group known to have click reactivity may be an alkene.

Implantable medical devices with an activated surface in accordance with this disclosure are fabricated from a substrate having applied thereto a coating including a polymeric material possessing a core and at least one functional group known to have click reactivity. The coating thus provides the implantable medical device with a plurality of functional groups known to have click reactivity at the surface thereof.

DETAILED DESCRIPTION OF EMBODIMENTS

Implantable medical devices in accordance with the present disclosure are prepared from a substrate having applied thereto a coating including a polymeric material possessing a core and at least one functional group known to have click reactivity. The coating thus provides the implantable medical device with a plurality of functional groups known to have click reactivity at the surface thereof.

The Polymeric Substrate

The substrate of the medical devices described herein may be made from any biocompatible polymer. The biocompatible polymer may be a homopolymer or a copolymer, including random copolymer, block copolymer, or graft copolymer. The biocompatible polymer may be a linear polymer, a branched polymer, or a dendrimer. The biocompatible polymer may be bioabsorbable or non-absorbable and may be of natural or synthetic origin.

Examples of suitable biodegradable polymers from which the substrate of the medical devices described herein may be made include, but are not limited to polymers such as those made from alpha-hydroxy acids (e.g. lactic acid, glycolic acid, and the like), lactide, glycolide, ϵ -caprolactone, δ -valerolactone, carbonates (e.g., trimethylene carbonate, tetramethylene carbonate, and the like), dioxanones (e.g., 1,4-dioxanone), δ -valerolactone, 1,4-dioxepanones (e.g., 1,4-dioxepan-2-one and 1,5-dioxepan-2-one), ethylene glycol, ethylene oxide, esteramides, hydroxy alkanoates (e.g. γ -hydroxyvalerate, β -hydroxypropionate, 3-hydroxybuterate, and the like), poly(ortho esters), tyrosine carbonates, polyimide carbonates, polyimino carbonates such as poly(bisphenol A-iminocarbonate) and poly(hydroquinone-iminocarbonate), polyurethanes, polyanhydrides, polymer drugs (e.g., polydiflunisol, polyaspirin, and protein therapeutics) and copolymers and combinations thereof. Suitable natural biodegradable polymers include collagen, cellulose, poly(amino acids), polysaccharides, hyaluronic acid, gut, copolymers and combinations thereof.

Examples of suitable non-degradable polymers from which the substrate of the medical devices described herein may be made include, but are not limited to fluorinated polymers (e.g. fluoroethylenes, propylenes, fluoroPEGs), polyolefins such as polyethylene, polyesters such as polyethylene terephthalate (PET), nylons, polyamides, polyurethanes, silicones, ultra high molecular weight polyethylene (UHMWPE), polybutesters, polyaryletherketone, copolymers and combinations thereof.

The biocompatible polymeric substrate may be fabricated into any desired physical form. The polymeric substrate may be fabricated for example, by spinning, casting, molding or

any other fabrication technique known to those skilled in the art. The polymeric substrate may be made into any shape, such as, for example, a fiber, sheet, rod, staple, clip, needle, tube, foam, or any other configuration suitable for a medical device. Where the polymeric substrate is in the form of a fiber, the fiber may be formed into a textile using any known technique including, but not limited to, knitting, weaving, tatting and the like. It is further contemplated that the polymeric substrate may be a non-woven fibrous structure.

The present biocompatible polymeric substrate can be part of any medical device of being implanted at a target location. Some non-limiting examples include fibers, monofilaments, multifilaments, surgical meshes, ligatures, sutures, staples, patches, slings, foams, pellicles, films, barriers, stents, catheters, shunts, grafts, coil, inflatable balloon, and the like. The implantable device can be intended for permanent or temporary implantation.

The Coating

The coating applied to the substrate in accordance with the present disclosure includes a polymer having at least one functional group known to have click reactivity. The polymer used in the coating possesses a core that is functionalized with one or more reactive members.

The core of the polymer may be any suitable biocompatible polymer. The core may be a homopolymer or a copolymer, including random copolymer, block copolymer, or graft copolymer. The core may be a linear polymer, a branched polymer, or a dendrimer. The core of may be a natural material or a synthetic material and may be bioabsorbable or non-bioabsorbable. It should of course be understood that any combination of natural, synthetic, bioabsorbable and non-bioabsorbable materials may be used to form the implantable medical device.

Some non-limiting examples of synthetic materials from which the core may be prepared include, but are not limited to poly(lactic acid), poly(glycolic acid), poly(lactide), poly(glycolide), poly(trimethylene carbonate), poly(p-dioxanone), polyhydroxybutyrate, polyphosphazine, polyesters, poly(ethylene terephthalate), ultra-high molecular weight polyethylene, poly(ethylene glycol)s, poly(ethylene oxide)s, polyacrylamides, poly(hydroxyethyl methylacrylate), poly(vinylpyrrolidone), poly(vinyl alcohol)s, poly(acrylic acid), polyacetate, polycaprolactone, polypropylene, aliphatic polyesters, glycerols, poly(amino acids), copoly(ether-esters), poly(alkylene oxalate)s, poly(saccharides), polyamides, poly(iminocarbonates), polyoxaesters, polyorthoesters, polyphosphazenes, biopolymers, polymer drugs and copolymers, block copolymers, homopolymers, blends and combinations thereof. Suitable natural polymers from which the core may be prepared include collagen, cellulose, poly(amino acids), polysaccharides, chitosan and chitosan derivatives (e.g., chitosan acetate/formate polymers), hyaluronic acid, gut, copolymers and combinations thereof.

In preparing a coating in accordance with the present disclosure, the polymer may be commercially available pre-functionalized cores or may be synthesized. It is contemplated that a plurality of different reactive members may be present and that they may be terminally located, or alternatively located along the length of the polymer chain. In embodiments, the polymer has from about 2 to about 50 reactive members.


Examples of the types of reactions that are known to have click reactivity include cycloaddition reactions. Cycloaddition reactions can be used to form the medical devices, for example fibers, of the present disclosure. These reactions represent highly specific reactant pairs that have a chemoselective nature, meaning that they mainly react with each other

5

and not with other functional members (i.e. different from functional groups and reactive members herein). One example of a cycloaddition reaction is the Huisgen 1,3-dipolar cycloaddition of a dipolarophile with a 1,3 dipolar component that produce five membered (hetero)cycles. Examples of dipolarophiles are alkenes, alkynes, and molecules that possess related heteroatom functional groups, such as carbonyls and nitriles. Specifically, another example is the 2+3 cycloaddition of alkyl azides and acetylenes. Other cycloaddition reactions include Diels-Alder reactions of a conjugated diene and a dienophile (such as an alkyne or alkene).

Other examples of the types of reactions that are known to have click reactivity include a hydrosilation reaction of H—Si and simple non-activated vinyl compounds, urethane formation from alcohols and isocyanates, Menshutkin reactions of tertiary amines with alkyl iodides or alkyl trifluoromethanesulfonates, Michael additions, e.g., the very efficient maleimide-thiol reaction, atom transfer radical addition reactions between $\text{—SO}_2\text{Cl}$ and an olefin ($\text{R}^1, \text{R}^2\text{—C=C—R}^3, \text{R}^4$), metathesis, Staudinger reaction of phosphines with alkyl azides, oxidative coupling of thiols, many of the procedures already used in dendrimer synthesis, especially in a convergent approach, which require high selectivity and rates, nucleophilic substitution, especially of small strained rings like epoxy and aziridine compounds, carbonyl chemistry like formation of ureas, and addition reactions to carbon-carbon double bonds like dihydroxylation. Therefore, attached functionality may be chosen from acetylene bond, an azido-group, a nitrile group, acetylenic, amino group, phosphino group. The click chemistry reaction may result in the addition of a functional group selected from amino, primary amino, hydroxyl, sulfonate, benzotriazole, bromide, chloride, chloroformate, trimethylsilane, phosphonium bromide or bio-responsive functional group including polypeptides, proteins and nucleic acids, to the polymer.

Thus, suitable reactive members that may be applied to the core include, for example, an amine, sulfate, thiosl, hydroxyl, azides, alkynes, alkenes, carboxyl groups, aldehyde groups, sulfone groups, vinylsulfone groups, isocyanate groups, acid anhydride groups, epoxide groups, aziridine groups, episulfide groups, groups such as $\text{—CO}_2\text{N}(\text{COCH}_2)_2$, $\text{—CO}_2\text{N}(\text{COCH}_2)_2$, $\text{—CO}_2\text{H}$, —CHO , —CHOCH_2 , —N=C=O , $\text{—SO}_2\text{CH=CH}_2$, $\text{—N}(\text{COCH}_2)_2$, $\text{—S—S—}(\text{C}_5\text{H}_4\text{N})$, and/or groups of the following structures wherein X is halogen and R is hydrogen or C_1 to C_4 alkyl:



In embodiments, the functional group known to have click reactivity is selected from the group consisting in thiols, azides, alkynes and alkenes.

The core of the polymer can be provided with click reactive members using any variety of suitable chemical processes.

For example, the monomers from which the core is made can be functionalized so that the reactive members appear along the length of the core. In such embodiments, monomers can be initially functionalized with a group such as a halogen to provide a reactive site at which the desired first click reactive member can be attached after polymerization. Thus, for example, a cyclic lactone (e.g., glycolide, lactide, caprolactone, etc.) can be halogenated and then polymerized using

6

known techniques for ring opening polymerization. Once polymerized, the halogenated sites along the resulting polyester chain can be functionalized with a click reactive member, for example, by converting pendant chlorides on the core into azides by reaction with sodium azide. See, R. Riva et al., *Polymer* 49, pages 2023-2028 (2008) for a description of such reaction schemes. Other methods for functionalizing lactones are described in Jérôme et al., *Advanced Drug Delivery Reviews*, 60, pages 1056-1076 (2008) and Shi et al., *Biomaterials*, 29, pages 1118-1126 (2008). The entire disclosure of each of these three articles is incorporated herein by this reference. Alternatively, the polymer or copolymer backbone may be halogenated using methods similar to those described by Nottelet et al., *Biomaterials*, 27, pages 4948-4954 (2006). Once halogenated, the backbone can be functionalized with a click reactive functionality by reacting it with a hydroxyacid under condition described by Shi et al. *Biomaterials*, 29, pages 1118-1126 (2008) followed by reaction with sodium azide. The halogen may also be converted directly to the alkyne by reacting it with an alcoholic alkyne such as propargyl alcohol.

Those skilled in the art reading this disclosure will readily envision chemical reactions for activating other core materials to render them suitable for use in coatings in the presently described methods.

Applying the Coating to the Substrate

A composition containing the functionalized polymer described herein can be applied to the substrate employing techniques known to one skilled in the art, e.g., by dipping, wiping, spraying, total immersion, co-extrusion, etc. For example, the coating may be applied by passing the substrate through a solution of the polymer, passing the substrate past a brush or other coating solution applicator, or passing the substrate past one or more spray nozzles dispensing the suture coating solution. The substrate wetted with the coating composition can be passed through or held in a drying oven for a time and at a temperature sufficient to vaporize and drive off the solvent.

The coating composition may take the form of any solution, suspension, semi-solid, or solid material capable of allowing the functionalized polymer to be applied as a coating to the substrate. The polymer may be in granular, pellet, or powder form, or alternatively, may be in a dilute solution. Suitable solvents which may be utilized to form a dilute solution include any biocompatible solvent within the purview of those skilled in the art which will not interfere with the reaction of the reactive members of the first and second precursors. Suitable solvents which may be utilized include, for example, polar solvents such as water, ethanol, triethylene glycol, dimethyl sulfoxide, glymes (such as diglyme, triglyme, tetraglyme, and the like), polyethylene glycols, methoxy-polyethylene glycols, dimethylformamide, dimethylacetamide, gamma-butyrolactone, n-methylpyrrolidone, ketones such as methyl ethyl ketone, cyclohexanone, diethylene glycol monomethyl ether acetate, diethylene glycol monobutyl ether acetate, diethylene glycol monomethyl ether, diethylene glycol monoethyl ether, diethylene glycol monobutyl ether, diethylene glycol monoisobutyl ether, diisobutyl ketone, diacetone alcohol, ethyl amyl ketone, ethyl lactate, and the like. In other embodiments, solvents such as tetrahydrofuran, ethyl acetate, isopropyl acetate, butyl acetate, isopropanol, butanol, acetone, and the like, may be utilized. In embodiments, combinations of any of the foregoing solvents may be utilized to form a dilute solution. The amount of solvent used will depend on a number of factors, including the particular polymer(s) to be employed in the coating composition.

In each case, the resulting coated substrate possesses click reactive functional groups at the surface thereof.

The present medical devices may further be use for delivery of a bioactive agent. Thus, in some embodiments, at least one bioactive agent may be combined with polymer to form the coating composition. The agents may be freely admixed with the functionalized polymer or may be tethered to the polymers through any variety of chemical bonds. In these embodiments, the present devices can also serve as a vehicle for delivery of the bioactive agent. The term "bioactive agent," as used herein, is used in its broadest sense and includes any substance or mixture of substances that have clinical use. Consequently, bioactive agents may or may not have pharmacological activity per se, e.g., a dye, or fragrance. Alternatively a bioactive agent could be any agent which provides a therapeutic or prophylactic effect, a compound that affects or participates in tissue growth, cell growth, cell differentiation, an anti-adhesive compound, a compound that may be able to invoke a biological action such as an immune response, or could play any other role in one or more biological processes. It is envisioned that the bioactive agent may be applied to the present devices in any suitable form of matter, e.g., films, powders, liquids, gels and the like.

Examples of classes of bioactive agents which optionally may be utilized in accordance with the coatings of the present disclosure include anti-adhesives, antimicrobials, analgesics, antipyretics, anesthetics, antiepileptics, antihistamines, anti-inflammatories, cardiovascular drugs, diagnostic agents, sympathomimetics, cholinomimetics, antimuscarinics, anti-spasmodics, hormones, growth factors, muscle relaxants, adrenergic neuron blockers, antineoplastics, immunogenic agents, immunosuppressants, gastrointestinal drugs, diuretics, steroids, lipids, lipopolysaccharides, polysaccharides, platelet activating drugs, clotting factors and enzymes. It is also intended that combinations of bioactive agents may be used.

Anti-adhesive agents can be used to prevent adhesions from forming between the implantable medical device and the surrounding tissues opposite the target tissue. In addition, anti-adhesive agents may be used to prevent adhesions from forming between the coated implantable medical device and the packaging material. Some examples of these agents include, but are not limited to hydrophilic polymers such as poly(vinyl pyrrolidone), carboxymethyl cellulose, hyaluronic acid, polyethylene oxide, poly vinyl alcohols, and combinations thereof.

Suitable antimicrobial agents which optionally may be included as a bioactive agent in the coating of the present disclosure include triclosan, also known as 2,4,4'-trichloro-2'-hydroxydiphenyl ether, chlorhexidine and its salts, including chlorhexidine acetate, chlorhexidine gluconate, chlorhexidine hydrochloride, and chlorhexidine sulfate, silver and its salts, including silver acetate, silver benzoate, silver carbonate, silver citrate, silver iodate, silver iodide, silver lactate, silver laurate, silver nitrate, silver oxide, silver palmitate, silver protein, and silver sulfadiazine, polymyxin, tetracycline, aminoglycosides, such as tobramycin and gentamicin, rifampicin, bacitracin, neomycin, chloramphenicol, miconazole, quinolones such as oxolinic acid, norfloxacin, nalidixic acid, pefloxacin, enoxacin and ciprofloxacin, penicillins such as oxacillin and piperacil, nonoxynol 9, fusidic acid, cephalosporins, and combinations thereof. In addition, antimicrobial proteins and peptides such as bovine lactoferrin and lactoferricin B may be included as a bioactive agent in the bioactive coating of the present disclosure.

Other bioactive agents which may be included as a bioactive agent in the coating composition applied in accordance

with the present disclosure include: local anesthetics; non-steroidal antifertility agents; parasympathomimetic agents; psychotherapeutic agents; tranquilizers; decongestants; sedative hypnotics; steroids; sulfonamides; sympathomimetic agents; vaccines; vitamins; antimalarials; anti-migraine agents; anti-parkinson agents such as L-dopa; anti-spasmodics; anticholinergic agents (e.g. oxybutynin); antitussives; bronchodilators; cardiovascular agents such as coronary vasodilators and nitroglycerin; alkaloids; analgesics; narcotics such as codeine, dihydrocodeinone, meperidine, morphine and the like; non-narcotics such as salicylates, aspirin, acetaminophen, d-propoxyphene and the like; opioid receptor antagonists, such as naltrexone and naloxone; anti-cancer agents; anti-convulsants; anti-emetics; antihistamines; anti-inflammatory agents such as hormonal agents, hydrocortisone, prednisolone, prednisone, non-hormonal agents, allopurinol, indomethacin, phenylbutazone and the like; prostaglandins and cytotoxic drugs; chemotherapeutics, estrogens; antibacterials; antibiotics; anti-fungals; anti-virals; anticoagulants; anticonvulsants; antidepressants; antihistamines; and immunological agents.

Other examples of suitable bioactive agents which may be included in the coating composition include viruses and cells, peptides, polypeptides and proteins, analogs, muteins, and active fragments thereof, such as immunoglobulins, antibodies, cytokines (e.g. lymphokines, monokines, chemokines), blood clotting factors, hemopoietic factors, interleukins (IL-2, IL-3, IL-4, IL-6), interferons (β -IFN, (α -IFN and γ -IFN), erythropoietin, nucleases, tumor necrosis factor, colony stimulating factors (e.g., GCSF, GM-CSF, MCSF), insulin, anti-tumor agents and tumor suppressors, blood proteins, fibrin, thrombin, fibrinogen, synthetic thrombin, synthetic fibrin, synthetic fibrinogen, gonadotropins (e.g., FSH, LH, CG, etc.), hormones and hormone analogs (e.g., growth hormone), vaccines (e.g., tumoral, bacterial and viral antigens); somatostatin; antigens; blood coagulation factors; growth factors (e.g., nerve growth factor, insulin-like growth factor); bone morphogenic proteins, TGF- β , protein inhibitors, protein antagonists, and protein agonists; nucleic acids, such as antisense molecules, DNA, RNA, RNAi; oligonucleotides; polynucleotides; and ribozymes.

Medical devices having an activated surface in accordance with the present disclosure can be used for a variety of purposes. For example, in embodiments they may be used for drug delivery. In such embodiments, the drug to be delivered is functionalized with one or more reactive members that are complementary to the reactive members in the coating at the surface of the device. By "complementary" it is meant that the reactive members on the drug to be delivered are able to interact with the reactive members in the coating at the surface of the device to covalently bond the drug to be delivered to the surface of the device.

In other embodiments, the medical device having an activated surface in accordance with the present disclosure can be attached to biological tissue by functionalizing tissue with one or more reactive member that are complementary to the reactive members in the coating at the surface of the device. Biological tissue can be provided with reactive member that are complementary to the reactive members in the coating at the surface of the device by conjugation of such groups to various components of tissue such as proteins, lipids, oligosaccharides, oligonucleotides, glycans, including glycosaminoglycans. In embodiments, the complementary groups are attached directly to components of the tissue. In other embodiments, the complementary groups are attached to components of the tissue via a linker. In either case, situating the complementary groups on the tissue can be accom-

9

plished by suspending the reactive member in a solution or suspension and applying the solution or suspension to the tissue such that the reactive member binds to a target. The solution or suspension may be poured, sprayed or painted onto the tissue, whereupon the reactive members are incorporated into the tissue.

Those skilled in the art reading this disclosure will readily envision other uses for the activated medical devices described herein.

While several embodiments of the disclosure have been described, it is not intended that the disclosure be limited thereto, as it is intended that the disclosure be as broad in scope as the art will allow and that the specification be read likewise. Therefore, the above description should not be construed as limiting, but merely as exemplifications of embodiments. Those skilled in the art will envision other modifications within the scope and spirit of the claims appended hereto.

What is claimed is:

1. A medical device comprising a polymeric textile having a coating, the coating comprising a natural polymer possessing a functional group having click reactivity selected from the group consisting of thiols, azides, alkynes and alkenes, wherein the coating imparts an activated surface to the textile via the functional group having click reactivity, wherein the natural polymer is selected from the group consisting of chitosan, collagen, hyaluronic acid, polysaccharides and copolymers and combinations thereof.

2. The medical device according to claim 1, wherein the functional group known to have click reactivity is a thiol.

10

3. The medical device according to claim 1, wherein the functional group known to have click reactivity is an azide.

4. The medical device according to claim 1, wherein the functional group known to have click reactivity is an alkyne.

5. The medical device according to claim 1, wherein the functional group known to have click reactivity is an alkene.

6. The medical device according to claim 1, wherein the natural polymer is chitosan.

7. The medical device of claim 1, wherein the polymeric textile is a surgical mesh.

8. The medical device of claim 1, wherein the polymeric textile is a sling.

9. The medical device of claim 1, further comprising a bioactive agent possessing a functional group having click reactivity complementary to the functional group having click reactivity of the coating, wherein the bioactive agent is covalently bonded to the surface of the coated polymeric textile via the activated surface.

10. The medical device of claim 9, wherein the bioactive agent is selected from the group consisting of anti-adhesives, antimicrobials, analgesics, antipyretics, anesthetics, antiepileptics, antihistamines, anti-inflammatories, cardiovascular drugs, diagnostic agents, synipathomimetics, cholinomimetics, anti-ics, antispasmodics, muscle relaxants adrenergic neuron Mockers, antineoplastics, immunogenic agents, immunosuppressants, gastrointestinal drugs, diuretics, steroids, lipids, platelet activating drugs, clotting factors chemotherapeutics and combinations thereof.

* * * * *